...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of endocrinology >Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone
【24h】

Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone

机译：甲亢恢复过程中骨代谢正常化的机制：硬化素和甲状旁腺激素的潜在作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sclerostin, a protein expressed by osteocytes, is a negative regulator of bone formation. The aim of the study was to investigate the relationship between parathyroid hormone (PTH) and markers of bone metabolism and changes of sclerostin concentrations before and after treatment of hyperthyroidism. Patients and Methods. The study involved 33 patients (26 women), age (mean ± SD) 48 ± 15 years, with hyperthyroidism. Serum sclerostin, PTH, calcium, and bone markers [osteocalcin (OC) and collagen type I cross-linked C-telopeptide I (CTX)] were measured at diagnosis of hyperthyroidism and after treatment with thiamazole. Results. After treatment of hyperthyroidism a significant decrease in free T3 (FT3) and free T4 (FT4) concentrations was accompanied by marked decrease of serum sclerostin (from 43.7 ± 29.3 to 28.1 ± 18.4 pmol/L; p < 0.001), OC (from 35.6 ± 22.0 to 27.0 ± 14.3 ng/mL; p < 0.001), and CTX (from 0.49 ± 0.35 to 0.35 ± 0.23 ng/dL; p < 0.005), accompanied by an increase of PTH (from 29.3 ± 14.9 to 39.8 ± 19.8; p < 0.001). During hyperthyroidism there was apositive correlation between sclerostin and CTX (rs = 0.41, p < 0.05) and between OC and thyroid hormones (with FT3 rs = 0.42, with FT4 rs = 0.45, p < 0.05). Conclusions. Successful treatment of hyperthyroidism results in a significant decrease in serum sclerostin and bone markers concentrations, accompanied by an increase of PTH.
机译：硬化蛋白是由骨细胞表达的蛋白质，是骨形成的负调节剂。该研究的目的是研究甲亢治疗前后甲状旁腺激素（PTH）与骨代谢标志物和硬化素浓度变化之间的关系。患者和方法。该研究纳入了33名甲亢患者（26名女性），年龄（平均±SD）48±15岁。在诊断甲状腺功能亢进症和噻唑治疗后，测量血清硬化素，PTH，钙和骨标志物[骨钙蛋白（OC）和I型胶原交联的C-端肽I（CTX）]。结果。治疗甲状腺功能亢进症后，游离T3（FT3）和游离T4（FT4）浓度显着降低，同时血清硬化素显着降低（从43.7±29.3降至28.1±18.4 pmol / L; p <0.001），OC（从35.6） ±22.0至27.0±14.3 ng / mL; p <0.001）和CTX（从0.49±0.35至0.35±0.23 ng / dL; p <0.005），伴随着PTH的增加（从29.3±14.9至39.8±19.8） ; p <0.001）。甲状腺功能亢进期间，硬化素和CTX之间呈正相关（rs = 0.41，p <0.05），而OC和甲状腺激素之间呈正相关（FT3 rs = 0.42，FT4 rs = 0.45，p <0.05）。结论甲状腺功能亢进症的成功治疗可导致血清硬化素和骨标志物浓度显着降低，并伴随PTH升高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号